Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in previously treated advanced squamous NSCLC
NCT02409368Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2015
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of nivolumab in squamous cell carcinoma of the lung (SCCL), sponsored by Bristol Myers Squibb. Started Apr 2015; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02409368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02409368.